

SCIENTIFIC REPORTS



OPEN

The epidemiology of hepatitis C virus in Central Asia: Systematic review, meta-analyses, and meta-regression analyses

Welathanthrige S. P. Botheju¹, Fawzi Zghyer¹, Sarwat Mahmud², Assel Terlikbayeva³, Nabila El-Bassel⁴ & Laith J. Abu-Raddad ^{2,5,6}

The objective was to delineate hepatitis C virus (HCV) epidemiology in countries of Central Asia (CA), specifically Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, and Uzbekistan. A systematic review was conducted guided by the Cochrane Collaboration Handbook, and reported using PRISMA guidelines. Meta-analyses were performed using DerSimonian-Laird random-effects models with inverse variance weighting. Random-effects meta-regression analyses were performed on general population studies. The systematic review identified a total of 208 HCV prevalence measures. No incidence or Turkmenistan studies were identified. Meta-analyses estimated HCV prevalence among the general population at 0.7% (95%CI: 0.7–0.8%) in Kazakhstan, 2.0% (95%CI: 1.7–2.4%) in Kyrgyzstan, 2.6% (95%CI: 1.7–3.6%) in Tajikistan, and 9.6 (95%CI: 5.8–14.2%) in Uzbekistan. Across CA, the pooled mean prevalence was 13.5% (95%CI: 10.9–16.4%) among non-specific clinical populations, 31.6% (95%CI: 25.8–37.7%) among populations with liver-related conditions, and 51.3% (95%CI: 46.9–55.6%) among people who inject drugs. Genotypes 1 (52.6%) and 3 (38.0%) were most frequent. Evidence was found for statistically-significant differences in prevalence by country, but not for a temporal decline in prevalence. CA is one of the most affected regions by HCV infection with Uzbekistan enduring one of the highest prevalence levels worldwide. Ongoing HCV transmission seems to be driven by injecting drug use and healthcare exposures.

With approximately 71 million people chronically infected worldwide, hepatitis C virus (HCV) related morbidities place a strain on healthcare systems globally¹. Since the recent development of direct-acting antivirals (DAA), a breakthrough treatment which provides opportunities to reduce HCV infection and disease burden^{2,3}, the World Health Organization (WHO) has set a target for the elimination of HCV as a public health concern by 2030^{4,5}. As such, an understanding of HCV epidemiology and risk factors for HCV infection worldwide is essential for developing targeted and cost-effective preventative and treatment interventions, to achieve the global target and eliminate HCV.

Geographically, for the purpose of this study, Central Asia (CA) encompasses five countries: Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, and Uzbekistan. Since independence from the Soviet Union, these countries have been undergoing difficult political, social, and economic transition^{6,7}. The public health and healthcare infrastructure has deteriorated, resulting in a decline in life expectancy, a rising burden of diseases, and re-emergence of infectious diseases^{7,8}. Though the region is perceived to have one of the highest HCV prevalence levels worldwide^{9,10}, HCV epidemiology and the drivers of HCV transmission remain poorly characterized.

¹Weill Cornell Medicine - Qatar, Cornell University, Qatar Foundation - Education City, Doha, Qatar. ²Infectious Disease Epidemiology Group, Weill Cornell Medicine - Qatar, Cornell University, Qatar Foundation - Education City, Doha, Qatar. ³Global Health Research Center of Central Asia in Kazakhstan, Almaty, Kazakhstan. ⁴Social Intervention Group, Columbia University School of Social Work, New York, New York, USA. ⁵Department of Healthcare Policy and Research, Weill Cornell Medicine, Cornell University, New York, New York, USA. ⁶College of Health and Life Sciences, Hamad bin Khalifa University, Doha, Qatar. Welathanthrige S. P. Botheju, Fawzi Zghyer and Sarwat Mahmud contributed equally. Correspondence and requests for materials should be addressed to L.J.A.-R. (email: lja2002@qatar-med.cornell.edu)

Our objective was to delineate HCV epidemiology in CA by (1) performing a systematic review of all available records of HCV antibody incidence and/or antibody prevalence among the different population categories, (2) pooling all HCV antibody prevalence measures in the general population to estimate the country-specific population-level HCV prevalence, (3) estimating the number of HCV infected persons across countries of CA, (4) performing a secondary systematic review of all evidence on HCV genotype information, and (5) identifying sources of between-study heterogeneity and estimate their contribution to the variability in HCV prevalence among the general population.

Materials and Methods

The methodology in this study is informed and adapted from that of the systematic reviews of the Middle East and North Africa (MENA) HCV Epidemiology Synthesis Project^{11–19}. This methodology is summarized in the ensuing subsections, and additional information is available in respective publications from this project^{11–19}.

Sources of data and search strategy. Literature on HCV antibody incidence and/or antibody prevalence was systematically reviewed guided by the Cochrane Collaboration Handbook²⁰. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were used in reporting our results²¹ (Table S1). The data sources used in this study included international PubMed and EMBASE databases (up to 9th April, 2018), a Russian scientific database—Scientific Electronic Library (eLibrary.ru) (up to 9th April, 2018), and country-level reports. The search criteria was broad with no language restrictions (Fig. S1). Articles published after 1989 were included in this review, since this was the year in which HCV was first identified^{22,23}.

Selection of studies. Duplicate publications were found and removed using the reference manager software, Endnote. Screening of the remaining unique records' titles and abstracts were performed individually by WB and FZ. Articles that were considered relevant or potentially relevant underwent full-text screening, using our inclusion and exclusion criteria. The references of all full-text articles and literature reviews also underwent screening to find any further relevant articles that may have been overlooked.

Inclusion and exclusion criteria. The inclusion and exclusion criteria used were adapted from that of the MENA HCV Epidemiology Synthesis Project systematic reviews^{11–19}. The inclusion criteria consisted of any document reporting HCV antibody incidence and/or antibody prevalence in populations from Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, and Uzbekistan, based on primary data, and of any language. The exclusion criteria included studies conducted before 1989, studies that referred to HCV as non-A non-B hepatitis, case series, case reports, commentaries, editorials, letters to editors, and literature reviews. All records underwent a secondary independent screening for data on HCV genotypes, regardless of whether they reported HCV antibody incidence and/or antibody prevalence.

In the following subsections, the term 'report' is used to refer to any document with an outcome measure of interest, while a 'study' refers to stratifications of a specific outcome measure. As such, a single report may contribute multiple studies, and multiple reports of the same study (outcome measure) were recognized as duplicates and considered as one study.

Extraction and analyses of data. Data from all reports considered relevant were extracted by WB and FZ. Data from all reports were subsequently double extracted by SM to ensure consistency and minimize errors in extracted information. Extracted information included study details (author, year of publication, title, and journal), location of study, year(s) of data collection, study design, sampling method, risk population, number of participants included in the study, number of participants tested, type and name of serological test used to test for HCV, and the primary outcome (HCV incidence or/and HCV prevalence). Rounding HCV prevalence measures to two decimal places was conducted if they were below 1%, while the remaining measures were rounded to only one decimal place. When available, HCV ribonucleic acid (RNA) data were also extracted. All studies identified in the secondary independent screening for genotype information were also extracted into a separate extraction file. Risk factors for HCV infection were extracted if they were statistically-significant through multi-variable meta-regression. Extracted data were classified into population categories according to exposure risk to HCV infection, as presented in Fig. 1. The classification scheme was based on existing literature^{10,24,25}, and earlier reviews of HCV prevalence^{11–19}.

Quantitative assessment. HCV prevalence reports with a minimum of 50 participants were categorized and reported in our reporting tables by risk population. Meta-analyses of HCV prevalence measures were performed by risk population and country for all studies with at least 25 participants. In reports where HCV prevalence was reported for mixed-country samples, the study was included only in meta-analyses for CA as a region. In reports that included prevalence measures but no reported sample size, a sample size of 300 was imputed and the study was included in the review and meta-analyses. This sample size was deemed reasonable and conservative, given that the median sample size of included studies with a reported sample size was 348.

HCV prevalence for the total sample size was replaced with stratified prevalence whenever a minimum of 25 participants were available for each stratum. Stratifications were included based on a predefined order, where nationality was prioritized, then sex, year, region, and finally age. To avoid duplication one final stratification for each study was included.

Freeman-Tukey type arcsine square-root transformation was used to stabilize the variance of HCV prevalence measures²⁶. DerSimonian-Laird random-effects model was used to pool HCV prevalence (with inverse variance weighting). This model assumes a normal distribution of true effect sizes (that is HCV prevalence) across studies, and takes into account true heterogeneity as well as random chance effects across studies²⁷.

General population (populations at low risk)

These included blood donors, pregnant women, and healthy adults, among other general population groups.

Populations at intermediate risk

These included populations with a risk of exposure higher than that of the general population, but lower than populations at higher risk of exposure, such as sex workers (male, female, unspecified), men who have sex with men (MSM), prisoners, and healthcare workers (HCW), among others.

High risk clinical populations

These included clinical populations repeatedly exposed to blood transfusions and/or medical injections, such as hemodialysis, hemophilia, thalassemia, and multi-transfused patients, among others.

Non-specific clinical populations

These included clinical populations in which the risk of exposure cannot be ascertained with confidence, such as clinical populations with insufficient description of the population, and HIV patients, among others.

Populations with liver-related conditions

These included populations with various liver-related conditions of epidemiological significance to HCV infection, such as patients with chronic liver disease, acute hepatitis, liver cirrhosis, and hepatocellular carcinoma, among others.

People who inject drugs (PWID)

These included populations engaging in injecting drug use and therefore at a high risk of exposure.

Figure 1. Population classification into categories by risk of exposures to hepatitis C virus (HCV) infection.

Heterogeneity measures were also assessed. All forest plots were visually assessed and the Cochran's Q test was performed, with a p-value of <0.10 indicating statistically strong evidence^{27,28}. The I^2 measure and its confidence interval were assessed²⁷. The prediction interval was also calculated to estimate the range in which HCV prevalence of 95% of future studies will fall^{27,29}.

The number of HCV antibody-positive persons in each country was determined by multiplying the country-specific pooled mean HCV antibody prevalence estimate by the population size in each country. This was subsequently multiplied by the pooled mean fraction of HCV RNA positivity in antibody-positive persons (also commonly referred to as the "viremic rate"^{30,31}), to derive the number of HCV chronically-infected persons. The United Nations World Population Prospects database³² was used to obtain the population size of each country.

Since potential issues have been identified with the Freeman-Tukey type arcsine square-root transformation³³, a sensitivity analysis was performed to confirm the validity of our results in which the generalized linear mixed models (GLMM) method was used to perform meta-analyses.

A proportion of the general population data were on blood donors, a population typically including only healthy adults. Sensitivity analysis was performed to determine whether excluding blood donors could impact the pooled mean HCV prevalence estimate in the general population. This sensitivity analysis was done for each country separately, and for CA as a whole.

Based on established methodology²⁰, univariable and multivariable random-effects meta-regressions were performed to assess country-level associations with HCV prevalence and the sources of between-study heterogeneity in the general population. Variables included in the univariable models included country, general population subpopulations, study site, sample size (<100 or ≥ 100), sampling method (probability-based or non-probability-based), year of publication, and year of data collection. Variables with a p-value of <0.1 were included in the multivariable model. Variables were deemed significant in the final multivariable meta-regression if they had a p-value of <0.05 .

For each country and the whole CA, the frequency of each genotype was calculated. Individuals who were positive for mixed genotypes contributed separately to the number of each of the identified genotypes. The Shannon Diversity Index (H) was determined to assess the diversity of genotypes, with a higher score (out of 1.95) indicating more diversity³⁴.

The *meta* package³⁵ on R version 3.4.3³⁶ was used to perform the meta-analyses. The *metan* command on STATA 13³⁷ was used to perform meta-regressions.

Qualitative analysis. Using the Cochrane approach to surmise risk of bias (ROB), the quality of HCV incidence and/or prevalence measures was evaluated. Based on three quality domains, studies were classified into either *low* or *high* ROB. These domains included HCV ascertainment (biological assay or otherwise), sampling method (probability-based or non-probability-based), and response rate ($\geq 80\%$ of the target sample size was reached or otherwise).




Figure 2. Flow chart of the process by which articles were selected for inclusion in this systematic review of hepatitis C virus (HCV) incidence and prevalence in Central Asia, adapted from the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2009 guidelines²¹.

Studies with information missing for any of the three domains were classified with *unclear* ROB for that specific domain. Studies in which the reported HCV measures were acquired from patients' medical records, or from individuals voluntarily visiting facilities where routine blood screening is performed, were considered as having *low* ROB on strictly the response rate domain.

Studies with at least 100 participants were classified as having *high* precision, as informed by previous studies¹¹⁻¹⁹.

Results

Search results. Figure 2, adapting the PRISMA flow diagram²¹, shows the process by which studies were selected into this systematic review. A total of 771 citations were identified: 95 from PubMed, 129 from Embase, and 547 from the Scientific Electronic Library (eLibrary.ru). A total of 99 unique reports underwent full-text screening, after duplicates were removed and titles and abstracts were screened. From these, 69 reports were removed, the reasons for which are stated in Fig. 2. Eighteen reports were added to the systematic review from gray literature/unpublished data, and from screening of references of full-text articles and reviews. Finally, 47 reports qualified for inclusion in this systematic review, yielding no incidence measure and 208 prevalence measures.

In the secondary systematic review, all 771 citations were screened for HCV genotype information. After duplicates were removed and titles and abstracts of all unique reports were screened, 35 reports underwent full-text screening. Finally, 6 reports qualified for inclusion in this secondary systematic review (Fig. S2).

HCV antibody prevalence overview. We present here a synthesis of HCV prevalence in each country of CA. The 208 HCV prevalence measures included 67 measures from Kazakhstan, 96 from Kyrgyzstan, 20 from Tajikistan, 23 from Uzbekistan, and 2 from mixed-country samples. No study was identified from Turkmenistan (Fig. S8A).

Overall. In CA, HCV prevalence ranged from 0.5–13.1% among the general population, with a median of 2.0%. This included blood donors (number of studies (n) = 9), with HCV prevalence ranging from 0.9–7.3%, with a median of 1.5%; 0.5–6.0% among pregnant women (n) = 9, with a median of 1.5%; and 0.7–13.1% among other general populations (n) = 19, with a median of 2.0% (Table 1).

HCV prevalence ranged from 0.0–50.0% among populations at intermediate risk, with a median of 13.2%. These included prisoners, with HCV prevalence ranging from 7.0–50.0%, with a median of 32.0%; 0.0–28.0% among sex workers (male, female, unspecified), with a median of 11.0%; and 2.0–6.2% among HCW, with a median of 2.7% (Table S2).

HCV prevalence ranged from 4.0–40.3% among non-specific clinical populations, with a median of 8.5%. These included hospitalized populations with HCV prevalence ranging from 5.9–33.3%, with a median of 8.0%; and HIV patients with HCV prevalence ranging from 10.5–40.3%, with a median of 21.8% (Table 2).

HCV prevalence ranged from 16.6–46.0% among populations with liver-related conditions, with a median of 26.8%; and 17.0–90.2% among PWID, with a median of 51.0% (Table 3).

Country-level. In Kazakhstan, HCV prevalence ranged from 0.7–5.1% among the general population, with a median of 0.9%; and 2.0–50.0% among populations at intermediate risk, with a median of 29.0%. Only one study was identified among non-specific clinical populations, with an HCV prevalence of 40.3% in HIV patients³⁸. HCV prevalence ranged from 23.8–40.4% in populations with liver-related conditions, with a median of 26.6%; and 43.3–90.2% among PWID, with a median of 60.3%.

In Kyrgyzstan, HCV prevalence ranged from 0.8–5.0% among the general population, with a median of 2.0%; 0.0–35.0% among populations at intermediate risk, with a median of 7.0%; and 4.0–33.3% among non-specific clinical populations, with a median of 8.0%. No studies were identified among populations with liver-related conditions. HCV prevalence ranged from 17.0–60.4% among PWID, with a median of 46.4%.

In Tajikistan, HCV prevalence ranged from 0.5–7.3% among the general population, with a median of 3.9%. Only two studies were conducted among populations at intermediate risk³⁹, with HCV prevalence of 4.2% among sex workers (male, female, unspecified)⁴⁰, and 6.2% among HCW⁴¹. Only one study was conducted on non-specific clinical populations, with an HCV prevalence of 32.1% in HIV patients⁴¹. Only two studies were conducted on populations with liver-related conditions, reporting an HCV prevalence of 46.0%⁴² and 36.0%³⁹. HCV prevalence ranged from 24.9–67.1% among PWID, with a median of 32.6%.

No studies were identified from Turkmenistan.

In Uzbekistan, HCV prevalence among the general population ranged from 6.4–13.1%, with a median of 6.5%; 9.2–18.8% among populations at intermediate risk, with a median of 11.9%; 16.5–29.2% among non-specific clinical populations, with a median of 26.9%; 16.6–41.9% among populations with liver-related conditions, with a median of 23.4%; and 20.9–63.8% among PWID, with a median of 51.7%.

Pooled mean HCV prevalence estimates and estimated number of HCV infected persons. The national population-level HCV prevalence for each country, based on pooling the general population measures, were estimated at: 0.7% (95%CI: 0.7–0.8%) in Kazakhstan, 2.0% (95%CI: 1.7–2.4%) in Kyrgyzstan, 2.6% (95%CI: 1.7–3.6%) in Tajikistan, and 9.6% (95%CI: 5.8–14.2%) in Uzbekistan. For all countries combined, the pooled mean HCV prevalence was estimated at 2.2% (95%CI: 1.9–2.6%). Figure S8B maps the pooled mean HCV prevalence estimates for CA.

Across CA, the estimated pooled mean HCV prevalence was 14.6% (95%CI: 12.8–16.5%) among populations at intermediate risk; 13.5% (95%CI: 10.9–16.4%) among non-specific clinical populations; 31.6% (95%CI: 5.8–37.7%) among populations with liver-related conditions; and 51.3% (95%CI: 46.9–55.6%) among PWID. The results of pooling these populations for each country separately can be found in Table 4.

Forest plots for the meta-analyses can be found in the Supplementary Material (Figs S3–S7). In the majority of meta-analyses, statistically significant heterogeneity was observed (Cochrane's Q statistic's p-value was always <0.0001; Table 4). Most of the variation across studies was due to variation in effect size (HCV prevalence) rather than chance ($I^2 > 59.0\%$). The prediction intervals ranged from narrow to wide for the different meta-analyses. Collectively, the heterogeneity measures indicated high heterogeneity in HCV prevalence in each country and risk population category.

Too few studies reported HCV RNA viremic rate in the general population to warrant calculation of the pooled mean viremic rate for CA. Accordingly, the pooled mean viremic rate of 67.6% for MENA was used in calculating chronic-infection prevalence and the number of chronically-infected persons. This choice is justified by the fact that this measure is a biological measure that (in principle) should be largely independent of the region³¹, and given that CA and MENA countries are both developing countries. The highest number of chronically-infected persons was found in Uzbekistan at 2.1 million, followed by Tajikistan at 160,068, Kazakhstan at 87,087, and Kyrgyzstan at 82,917.

Author, year (citation)	Year(s) of data collection	Country of survey	Study site	Study design	Study sampling	Population	Sample size	HCV prevalence (%) ^a
Skorikova, 2015 ⁷⁸	2012	Kazakhstan	Blood transfusion center	CS	Conv	Blood donors	28,248	0.90
Nurgalieva, 2007 ⁴⁵	NS	Kazakhstan	Community	CS	Conv	General population	150	2.0
El-Bassel, 2011 ⁷⁹	2008	Kazakhstan	Community	CS	SRS	General population (female)	213	3.0
El-Bassel, 2011 ⁷⁹	2008	Kazakhstan	Community	CS	SRS	General population (male)	209	0.0
Dzhumagalieva, 2015 ⁸⁰	NS	Kazakhstan	Community	NS	NS	Pregnant women	300 [‡]	5.1
Khasanova, 2007 ⁸¹	2006	Kazakhstan	National	CS	Conv	Pregnant women	6,405	1.0
Blood-center, 2015 ⁸²	2015	Kazakhstan	Blood bank	CS	Conv	Blood donors	285,484	0.86
Tashtemirov, 2016 ⁸³	2016	Kazakhstan	Blood bank	CS	Conv	Blood donors	59,323	0.85
Mamaev, 2006 ⁸⁴	2005	Kyrgyzstan	Community	CS	Conv	Pregnant women	898	1.6
Djumagulova, 2016 ⁸⁵	2011	Kyrgyzstan	Community	CS	Conv	Blood donors	37,771	2.6
Djumagulova, 2016 ⁸⁵	2012	Kyrgyzstan	Community	CS	Conv	Blood donors	36,463	2.5
Djumagulova, 2016 ⁸⁵	2013	Kyrgyzstan	Community	CS	Conv	Blood donors	37,463	2.5
Djumagulova, 2016 ⁸⁵	2014	Kyrgyzstan	Community	CS	Conv	Blood donors	41,156	1.8
Djumagulova, 2016 ⁸⁵	2015	Kyrgyzstan	Community	CS	Conv	Blood donors	42,038	1.9
Djumagulova, 2016 ⁸⁵	2004	Kyrgyzstan	National	CS	Conv	General population	300 [‡]	2.0
Djumagulova, 2016 ⁸⁵	2005	Kyrgyzstan	National	CS	Conv	General population	300 [‡]	1.0
Djumagulova, 2016 ⁸⁵	2006	Kyrgyzstan	National	CS	Conv	General population	300 [‡]	5.0
Djumagulova, 2016 ⁸⁵	2007	Kyrgyzstan	National	CS	Conv	General population	300 [‡]	5.0
Djumagulova, 2016 ⁸⁵	2008	Kyrgyzstan	National	CS	Conv	General population	300 [‡]	2.0
Djumagulova, 2016 ⁸⁵	2009	Kyrgyzstan	National	CS	Conv	General population	300 [‡]	2.0
Djumagulova, 2016 ⁸⁵	2010	Kyrgyzstan	National	CS	Conv	General population	300 [‡]	5.0
Djumagulova, 2016 ⁸⁵	2011	Kyrgyzstan	National	CS	Conv	General population	300 [‡]	0.80
Djumagulova, 2016 ⁸⁵	2012	Kyrgyzstan	National	CS	Conv	General population	300 [‡]	4.0
Djumagulova, 2016 ⁸⁵	2013	Kyrgyzstan	National	CS	Conv	General population	300 [‡]	2.0
Djumagulova, 2016 ⁸⁵	2014	Kyrgyzstan	National	CS	Conv	General population	300 [‡]	5.0
Djumagulova, 2016 ⁸⁵	2013	Kyrgyzstan	National	CS	Conv	Pregnant women	300 [‡]	1.0
Djumagulova, 2016 ⁸⁵	2014	Kyrgyzstan	National	CS	Conv	Pregnant women	300 [‡]	1.4
Djumagulova, 2016 ⁸⁵	2015	Kyrgyzstan	National	CS	Conv	Pregnant women	300 [‡]	1.6
Djumagulova, 2016 ⁸⁵	2013	Kyrgyzstan	National	CS	Conv	Army recruits	300 [‡]	1.0
Djumagulova, 2016 ⁸⁵	2014	Kyrgyzstan	National	CS	Conv	Army recruits	300 [‡]	1.0
Bakhovadinov, 2016 ⁸⁶	2016	Kyrgyzstan	Blood bank	CS	Conv	Blood donors	46,780	1.8
Bahovadinov, 2010 ⁸⁷	2007–2009	Tajikistan	Community	CS	Conv	Blood donors	66,333	2.9
Asimov, 2015 ⁴¹	2006–2010	Tajikistan	Community	CS	SRS	Pregnant women	315	6.0
Asimov, 2015 ⁴¹	2006–2010	Tajikistan	Community	CS	SRS	Paid blood donors	68	7.3
Abdurashit, 2008 ⁸⁸	2005–2007	Tajikistan	National	CS	Conv	Pregnant women	1,554	0.50
Aklsalikh, 2017 ⁴⁰	NS	Tajikistan	Community	CS	Conv	Labor workers	415	4.8
Aklsalikh, 2017 ⁴⁰	NS	Uzbekistan	Community	CS	Conv	Labor workers	464	4.5
Kurbanov, 2003 ⁴³	2001	Uzbekistan	Clinical	CS	Conv	Blood donors, pregnant women	341	6.5
Ruzibakiev, 2001 ⁸⁹	1999–2000	Uzbekistan	Community	CS	SRS	General population	929	11.3
Ruzibakiev, 2001 ⁸⁹	1999–2000	Uzbekistan	Community	CS	SRS	Paid blood donors	346	6.4
Berger, 2015 ⁹⁰	1999–2000	Uzbekistan	Community	NS	NS	General population	300 [‡]	13.1
Glikberg, 1997	1995–1997	Israel [‡]	Community	CS	Conv	General population (Bukharian Jews)	102	26.5

Table 1. Studies reporting hepatitis C virus (HCV) prevalence among the general population in Central Asia (CA). Abbreviations: Conv, convenience; CS, cross-sectional; NS, not specified; SRS, simple random sampling. ^aPrevalence figures are as reported in the original reports, but rounded to one decimal place, provided the prevalence figure was over 1%. [‡]Study did not report sample size. The included sample size was imputed based on the median sample size of all studies that reported a sample size. [§]Study performed on immigrants from Central Asia.

In sensitivity analyses, the GLMM meta-analyses confirmed similar results for all risk populations (Table S3). Also in sensitivity analyses, after blood donor data were excluded, population-level HCV prevalence was overall similar across countries, and in CA as a whole (Table S4).

Meta-regressions and sources of heterogeneity. The results of the meta-regression for the general population is presented in Table 5. In the univariable meta-regression analyses, country, study site, sample size, and year of data collection were significant predictors (p -value < 0.1), and therefore were included in the final multivariable analysis. Notably, sampling method (probability-based versus non-probability-based) had no effect on observed HCV prevalence.

Author, year (citation)	Year(s) of data collection	Country of survey	Study site	Study design	Study sampling	Population	Sample size	HCV prevalence (%) ^a
Non-specific clinical populations								
Begaidarova, 2016 ³⁸	NS	Kazakhstan	Clinical	CS	Conv	HIV patients	181	40.3
Djumagulova, 2016 ⁸⁵	2004	Kyrgyzstan	National	CS	Conv	Clinical populations	300 [‡]	9.0
Djumagulova, 2016 ⁸⁵	2005	Kyrgyzstan	National	CS	Conv	Clinical populations	300 [‡]	8.0
Djumagulova, 2016 ⁸⁵	2006	Kyrgyzstan	National	CS	Conv	Clinical populations	300 [‡]	8.0
Djumagulova, 2016 ⁸⁵	2007	Kyrgyzstan	National	CS	Conv	Clinical populations	300 [‡]	8.0
Djumagulova, 2016 ⁸⁵	2008	Kyrgyzstan	National	CS	Conv	Clinical populations	300 [‡]	8.0
Djumagulova, 2016 ⁸⁵	2009	Kyrgyzstan	National	CS	Conv	Clinical populations	300 [‡]	7.0
Djumagulova, 2016 ⁸⁵	2010	Kyrgyzstan	National	CS	Conv	Clinical populations	300 [‡]	8.0
Djumagulova, 2016 ⁸⁵	2011	Kyrgyzstan	National	CS	Conv	Clinical populations	300 [‡]	8.0
Djumagulova, 2016 ⁸⁵	2012	Kyrgyzstan	National	CS	Conv	Clinical populations	300 [‡]	7.0
Djumagulova, 2016 ⁸⁵	2013	Kyrgyzstan	National	CS	Conv	Clinical populations	300 [‡]	5.9
Djumagulova, 2016 ⁸⁵	2014	Kyrgyzstan	National	CS	Conv	Clinical populations	300 [‡]	19.1
Djumagulova, 2016 ⁸⁵	2015	Kyrgyzstan	National	CS	Conv	Clinical populations	300 [‡]	33.3
Djumagulova, 2016 ⁸⁵	2014	Kyrgyzstan	National	CS	Conv	HIV patients	5,505	10.5
Djumagulova, 2016 ⁸⁵	2015	Kyrgyzstan	National	CS	Conv	HIV patients	6,110	11.5
Asimov, 2015 ⁴¹	2006–2010	Tajikistan	Community	CS	SRS	HIV patients	109	32.1
Kurbanov, 2003 ⁴³	2001	Uzbekistan	Clinical	CS	Conv	Hematological disease patients	186	26.9
Ruzibakiev, 2001 ⁸⁹	1999–2000	Uzbekistan	Community	CS	SRS	Hematological disease patients	72	29.2
Ruzibakiev, 2001 ⁸⁹	1999–2000	Uzbekistan	Community	CS	SRS	Renal disease patients	85	16.5
Djumagulova, 2016 ⁸⁵	2013	Kyrgyzstan	National	CS	Conv	Recipients (blood, tissue, organs, sperm)	300 [‡]	4.0
Djumagulova, 2016 ⁸⁵	2014	Kyrgyzstan	National	CS	Conv	Recipients (blood, tissue, organs, sperm)	300 [‡]	4.0
Populations with liver-related conditions								
Kurbanov, 2003 ⁴³	2001	Uzbekistan	Clinical	CS	Conv	Acute hepatitis patients	240	20.0
Kurbanov, 2003 ⁴³	2001	Uzbekistan	Clinical	CS	Conv	Chronic liver disease patients	234	41.9
Ruzibakiev, 2001 ⁸⁹	1999–2000	Uzbekistan	Community	CS	SRS	Acute hepatitis patients	96	16.6
Ruzibakiev, 2001 ⁸⁹	1999–2000	Uzbekistan	Community	CS	SRS	Chronic liver disease patients	164	26.8
Mirojov, 2013 ³⁹	NS	Tajikistan	Community	CS	NS	Liver cirrhosis patients	1,374	36.0
Ni, 2012 ⁹¹	2002–2010	China [‡]	Community	CS	Conv	Primary liver cancer patients	335	40.4
Khan, 2008 ⁴²	2006	Tajikistan	Clinical	CS	Conv	Patients with chronic liver disease	124	46.0
Nersesov, 2017 ⁹²	2017	Kazakhstan	Clinical	CS	Conv	Hepatocellular carcinoma patients	1,357	23.8
Baimakhanov, 2017 ⁸⁶	2017	Kazakhstan	Clinical	CS	Conv	Liver transplant patients	64	26.6

Table 2. Studies reporting hepatitis C virus (HCV) prevalence among clinical populations in Central Asia (CA). Abbreviations: Conv, convenience; CS, cross-sectional; NS, not specified; SRS, simple random sampling; ^aPrevalence figures are as reported in the original reports, but rounded to one decimal place, provided the prevalence figure was over 1%. [‡]Study did not report sample size. The included sample size was imputed based on the median sample size of all studies that reported a sample size. [‡]Study performed on immigrants from Central Asia.

Study site and year of data collection lost significance (p -value > 0.05) in the multivariable analysis—only country and sample size remained statistically significant. Relative to Kazakhstan, the prevalence in Kyrgyzstan, Tajikistan, and Uzbekistan was higher with an adjusted odds ratio (AOR) of 2.0 (95%CI: 1.1–3.4), 2.8 (95%CI: 1.4–5.6), and 10.0 (95%CI: 4.6–21.7), respectively. Sample size (> 100) was associated with lower HCV prevalence, with an AOR of 0.4 (95%CI: 0.1–1.0). Notably, the AOR for year of data collection was 1.0 (95%CI: 1.0–1.1)—there was thus no evidence for declines in HCV prevalence with time. The model explained 51.4% of the variability in HCV prevalence.

HCV RNA prevalence. Our search identified only four HCV RNA measures, all of which were reported among HCV antibody-positive individuals: 39.2% in a study on a general population⁴³, 100% in a study on HIV patients³⁸, 100% in a study on chronic hepatitis patients⁴², and 70.5% in a study on liver cirrhosis patients⁴².

HCV genotypes. HCV genotype information was available in six studies with a total of 382 HCV RNA positive individuals (Table S5). Only 0.5% of individuals were infected with multiple genotypes, while the remaining majority were infected with a single genotype. No genotype information was available for Kyrgyzstan and Turkmenistan.

The highest proportions of infections for each HCV genotype in CA as a whole were for genotype 1 at 52.6% and genotype 3 at 38.0%, followed by genotype 2 at 9.4%. Genotypes 4, 5, 6, and 7 were not identified. Genotype diversity tended towards being low, but varied across CA, with the highest diversity observed in Kazakhstan ($H = 1.04$ out of 1.95; 53.7%), followed by Uzbekistan ($H = 0.85$ out of 1.95; 43.6%), and Tajikistan ($H = 0.54$ out of 1.95; 27.5%). Collectively in CA, genotype diversity was rather low ($H = 0.93$ out of 1.95; 47.7%).

Author, year (citation)	Year(s) of data collection	Country of survey	Study site	Study design	Study sampling	Population	Sample size	HCV prevalence (%) ^a
Deryabina, 2015 ⁹³	NS	Kazakhstan	Community	CS	Conv	PWID	300 [†]	63.0
Zhussupov, 2007 ⁹⁴	2002	Kazakhstan	Community, NSP clinics	CS	Conv, SBS	PWID	1,426	79.8
Gilbert, 2010 ⁹⁵	2005–2006	Kazakhstan	NSP clinic	CS	Conv	PWID	80	58.9
El-Bassel, 2014 ⁹⁶	2009–2012	Kazakhstan	Community, NSP and HIV clinics	RCT ^b	Conv, SBS	PWID and non-injecting or injecting partners	600	77.0
El-Bassel, 2014 ⁹⁷	2009–2012	Kazakhstan	Community, NSP and HIV clinics	RCT ^b	Conv, SBS	PWID (females)	194	89.8
El-Bassel, 2013 ⁹⁸	2009–2012	Kazakhstan	Community, NSP and HIV clinics	RCT ^b	Conv, SBS	PWID	580	90.2
Zabransky, 2014 ⁹⁹	2003	Kazakhstan	Community	CS	Conv	PWID	300 [†]	57.2
Zabransky, 2014 ⁹⁹	2004	Kazakhstan	Community	CS	Conv	PWID	300 [†]	57.2
Zabransky, 2014 ⁹⁹	2005	Kazakhstan	Community	CS	Conv	PWID	300 [†]	63.1
Zabransky, 2014 ⁹⁹	2006	Kazakhstan	Community	CS	Conv	PWID	300 [†]	52.6
Zabransky, 2014 ⁹⁹	2007	Kazakhstan	Community	CS	Conv	PWID	300 [†]	47.6
Zabransky, 2014 ⁹⁹	2008	Kazakhstan	Community	CS	Conv	PWID	300 [†]	64.1
Zabransky, 2014 ⁹⁹	2009	Kazakhstan	Community	CS	Conv	PWID	300 [†]	60.3
Zabransky, 2014 ⁹⁹	2010	Kazakhstan	Community	CS	Conv	PWID	300 [†]	58.7
Zabransky, 2014 ⁹⁹	2011	Kazakhstan	Community	CS	Conv	PWID	300 [†]	61.2
Soliev, 2010 ¹⁰⁰	2009	Kazakhstan	National	CS	Conv	PWID	4,860	60.0
Ganina, 2016 ¹⁰¹	2013	Kazakhstan	National	CS	Conv	PWID		60.3
Ganina, 2016 ¹⁰¹	2014	Kazakhstan	National	CS	Conv	PWID	4,414	70.7
Rosenkranz, 2016 ¹⁰²	2016	Kazakhstan	Narcological Centers and Community	CS	Conv	PWID	600	43.3
Djumagulova, 2016 ⁸⁵	2013	Kyrgyzstan	National	CS	Conv	PWID	300 [†]	31.9
Djumagulova, 2016 ⁸⁵	2014	Kyrgyzstan	National	CS	Conv	PWID	300 [†]	40.4
Djumagulova, 2016 ⁸⁵	2015	Kyrgyzstan	National	CS	Conv	PWID	300 [†]	35.2
Djumagulova, 2016 ⁸⁵	2004	Kyrgyzstan	National	CS	Conv	PWID	300 [†]	56.0
Djumagulova, 2016 ⁸⁵	2005	Kyrgyzstan	National	CS	Conv	PWID	300 [†]	40.0
Djumagulova, 2016 ⁸⁵	2006	Kyrgyzstan	National	CS	Conv	PWID	300 [†]	45.0
Djumagulova, 2016 ⁸⁵	2007	Kyrgyzstan	National	CS	Conv	PWID	300 [†]	52.0
Djumagulova, 2016 ⁸⁵	2008	Kyrgyzstan	National	CS	Conv	PWID	300 [†]	44.0
Djumagulova, 2016 ⁸⁵	2009	Kyrgyzstan	National	CS	Conv	PWID	300 [†]	31.0
Djumagulova, 2016 ⁸⁵	2010	Kyrgyzstan	National	CS	Conv	PWID	300 [†]	17.0
Djumagulova, 2016 ⁸⁵	2011	Kyrgyzstan	National	CS	Conv	PWID	300 [†]	34.0
Djumagulova, 2016 ⁸⁵	2012	Kyrgyzstan	National	CS	Conv	PWID	300 [†]	53.0
Zabransky, 2014 ⁹⁹	2005	Kyrgyzstan	Community	CS	Conv	PWID	300 [†]	50.6
Zabransky, 2014 ⁹⁹	2006	Kyrgyzstan	Community	CS	Conv	PWID	300 [†]	48.4
Zabransky, 2014 ⁹⁹	2007	Kyrgyzstan	Community	CS	Conv	PWID	300 [†]	51.3
Zabransky, 2014 ⁹⁹	2008	Kyrgyzstan	Community	CS	Conv	PWID	300 [†]	47.5
Zabransky, 2014 ⁹⁹	2009	Kyrgyzstan	Community	CS	Conv	PWID	300 [†]	53.7
Zabransky, 2014 ⁹⁹	2010	Kyrgyzstan	Community	CS	Conv	PWID	300 [†]	50.4
Soliev, 2010 ¹⁰⁰	2009	Kyrgyzstan	National	CS	Conv	PWID	900	54.0
Drew, 2005 ¹⁰³	2004	Kyrgyzstan	NS	NS	NS	PWID	200	45.0
Drew, 2005 ¹⁰³	2004	Kyrgyzstan	NS	NS	NS	PWID	265	60.0
Rosenkranz, 2016 ¹⁰²	2016	Kyrgyzstan	Narcological Centers and Community	CS	Conv	PWID	900	21.2
Asimov, 2015 ⁴¹	2006–2010	Tajikistan	Community	CS	SRS	PWID	315	40.9
Beyrer, 2008 ⁴⁴	2004	Tajikistan	Community, NSP clinic	CS	Conv, SBS	PWID	240	67.1
Zabransky, 2014 ⁹⁹	2005	Tajikistan	Community	CS	Conv	PWID	300 [†]	43.1
Zabransky, 2014 ⁹⁹	2006	Tajikistan	Community	CS	Conv	PWID	300 [†]	45.0
Zabransky, 2014 ⁹⁹	2007	Tajikistan	Community	CS	Conv	PWID	300 [†]	31.1
Zabransky, 2014 ⁹⁹	2008	Tajikistan	Community	CS	Conv	PWID	300 [†]	29.9
Zabransky, 2014 ⁹⁹	2009	Tajikistan	Community	CS	Conv	PWID	300 [†]	32.6
Zabransky, 2014 ⁹⁹	2010	Tajikistan	Community	CS	Conv	PWID	300 [†]	27.8
Zabransky, 2014 ⁹⁹	2011	Tajikistan	Community	CS	Conv	PWID	300 [†]	24.9
Soliev, 2010 ¹⁰⁰	2009	Tajikistan	National	CS	Conv	PWID	1,657	33.0

Continued

Author, year (citation)	Year(s) of data collection	Country of survey	Study site	Study design	Study sampling	Population	Sample size	HCV prevalence (%) ^a
Kurbanov, 2003 ¹⁰⁴	2001	Uzbekistan	Clinical	CS	Conv	PWID	60	51.7
Ruzibakiev, 2001 ⁸⁹	1999–2000	Uzbekistan	Community	CS	SRS	PWID	51	62.7
Beyrer, 2008 ⁴⁴	2004	Uzbekistan	Community, NSP clinic	CS	Conv, SBS	PWID	58	63.8
Zabransky, 2014 ⁹⁹	2005	Uzbekistan	Community	CS	Conv	PWID	300 ^f	53.7
Zabransky, 2014 ⁹⁹	2007	Uzbekistan	Community	CS	Conv	PWID	300 ^f	35.5
Zabransky, 2014 ⁹⁹	2009	Uzbekistan	Community	CS	Conv	PWID	300 ^f	28.5
Zabransky, 2014 ⁹⁹	2011	Uzbekistan	Community	CS	Conv	PWID	300 ^f	20.9
Inogamov, 2008 ¹⁰⁵	2007	Uzbekistan	National	CS	Conv	PWID	3,743	36.0

Table 3. Studies reporting hepatitis C virus (HCV) prevalence among people who inject drugs (PWID) in Central Asia (CA). Abbreviations: Conv, convenience; CS, cross-sectional; NS, not specified; SRS, simple random sampling; PWID, people who inject drugs; RCT, randomized controlled trial; SBS, snowball sampling; NSP, needle and syringe exchange program; HIV, human immunodeficiency virus. ^aPrevalence figures are as reported in the original reports, but rounded to one decimal place, provided the prevalence figure was over 1%. ^bIn randomized controlled trials the extracted HCV prevalence measure was the cross-sectional baseline HCV prevalence measure. ^cStudy did not report sample size. The included sample size was imputed based on the median sample size of all studies that reported a sample size.

HCV risk factors. Only two studies reported statistically-significant risk factors for HCV infection after controlling for confounders. In Tajikistan, among PWID, daily injection, history of incarceration, and living/working outside of Tajikistan in the past 10 years, were associated with HCV infection⁴⁴. In Kazakhstan, among a general population, tattooing and (unexpectedly) towel sharing were reported as associated with HCV infection⁴⁵.

Quality assessment. Table S6 summarizes the results of the ROB assessment performed on HCV prevalence measures. The majority of measures were of high precision (94.7%), with a sample size ≥ 100 . Most measures were of low risk of bias in the HCV ascertainment domain, with 99% being based on biological assays, and 1% being based on self-reporting. Though most of the studies reported the name of the biological assay used to assess HCV antibody prevalence, the majority of studies (90%) did not explicitly report the generation of the assay. Among studies reporting the generation of the used assay, all used the more sensitive and specific 3rd generation enzyme-linked immunosorbent assays (ELISA) tests. The majority of studies employed non-probability-based sampling, and were characterized by a high response rate.

To summarize, 100% of studies had low ROB based on at least one ROB domain, 65.0% of studies had low ROB based on at least two ROB domains, and 13.4% of studies had low ROB based on all three ROB domains. No study had high ROB based on two or three ROB domains. In all, the quality assessment indicates reasonable though not optimal study quality.

Discussion

We presented, to our knowledge, the first systematic review and synthesis of HCV epidemiology in CA, a region perceived to be heavily affected by this infection^{9,10}. Our results indicated that HCV antibody prevalence varies across countries of CA, ranging from 0.7% in Kazakhstan to 9.6% in Uzbekistan (Table 4 and Fig. S8). Accordingly, HCV prevalence in Uzbekistan is considerably higher than global levels, and one of the highest worldwide^{9,10}. This finding is of concern considering that Uzbekistan is also the most populous country in CA, with 32 million inhabitants⁴⁶, and a country struggling with a weakened healthcare system since the collapse of the Soviet Union⁶. With an estimated 2.1 million chronically-infected persons, >80% of all chronically-infected persons in CA reside in Uzbekistan. Notably, Uzbekistan has also the highest rate of HIV among all countries in this region⁴⁷, and a main mode of transmission appears to be injecting drug use, a shared mode of transmission with HCV.

Remarkably, HCV prevalence does not appear to be decreasing with time in CA (Table 5), contrary to global trend^{48,49}. This may in part be reflective of the majority of studies from this region being reported more recently, with approximately 85% of all studies included in this review being from the last decade.

High HCV antibody prevalence was observed across all risk populations (Tables 1–3 and S2), and more so for PWID, HIV patients, and prisoners, suggesting a major role for injecting drug use in infection transmission. HCV antibody prevalence was also high in populations with liver-related conditions, suggesting a major role that HCV plays in liver disease burden in CA.

Strikingly, no studies were identified among high risk clinical populations such as haemodialysis, haemophilia, and thalassemia patients—the role of healthcare in transmission remains uncertain. However, the relatively high HCV antibody prevalence in non-specific clinical populations (Table 2), and HCV epidemiology in other soviet-era-related countries^{9,10,49,50}, suggest that healthcare could be a major mode of exposure, at least in earlier decades.

Subregional disparities in quality of healthcare services may have also contributed to the heterogeneity in HCV prevalence across CA⁵⁰. For example, in Uzbekistan, it appears (anecdotally) that there is an excessive practice of medical and non-medical invasive procedures, such as blood transfusions and bloodletting, in addition to poor infection control⁵¹, inadequate blood screening^{43,51,52}, and use of unsafe medical injections^{50,51}, all of which are probable causes for the high HCV prevalence in this country, as has been observed in other developing

	Studies	Samples	Prevalence	Pooled HCV prevalence	Heterogeneity measures			Pooled chronic infection prevalence	Population size ⁴⁶	Estimated number of HCV antibody positive persons	Estimated number of HCV chronically-infected persons
	Total n	Total N	Range (%) [†]	Mean (95% CI)	Q (p-value) ^a	I ² (confidence limits) ^b	Prediction interval (%) ^c	Mean (95% CI)			
	Kazakhstan										
General population	14	665,859	0.0–5.1	0.7 (0.7–0.8)	75.8 (p < 0.01)	82.9% (72.25–89.3%)	0.5–1.0	0.5 (0.5–0.5)	18,403,860	128,827 (128,827–147,231)	87,087 (87,087–99,528)
Populations at intermediate risk	36	13,175	2.0–50.0	24.4 (19.3–29.9)	1767.3 (p = 0)	98.0% (97.7–98.3%)	1.7–61.5				
Non-specific clinical populations	—	—	—	—	—	—	—				
Populations with liver-related conditions	3	1,756	23.8–40.4	30.1 (18.6–43.0)	34.2 (p < 0.01)	94.1% (86.3–97.5%)	0.0–100				
People who inject drugs	20	20,549	43.3–90.6	66.7 (61.8–71.5)	894.1 (p < 0.01)	97.9% (97.4–98.3%)	42.6–87.0				
Kyrgyzstan											
General population	22	200,560	0.7–5.0	2.0 (1.7–2.4)	195.8 (p < 0.01)	89.3% (85.1–92.3%)	1.1–3.2	1.4 (1.2–1.6)	6,132,932	122,659 (104,260–147,190)	82,917 (70,480–99,501)
Populations at intermediate risk	42	206,130	0.0–42.4	8.6 (7.3–10.0)	3560.1 (p = 0)	98.8% (98.7–99.0%)	2.1–18.6				
Non-specific clinical populations	16	15,815	4.0–33.3	9.3 (7.5–11.4)	188.5 (p < 0.01)	92.0% (88.7–94.4%)	2.9–18.8				
Populations with liver-related conditions	—	—	—	—	—	—	—				
People who inject drugs	22	7,715	17.0–60.4	43.4 (37.9–49.0)	512.4 (p < 0.01)	95.9% (94.8–96.8%)	18.2–70.6				
Tajikistan											
General population	6	115,465	0.5–7.4	2.6 (1.7–3.6)	219.6 (p < 0.01)	98.1% (97.1–98.8%)	0.4–6.4	1.8 (1.2–2.4)	9,107,211	236,787 (154,823–327,860)	160,068 (104,660–221,633)
Populations at intermediate risk	—	—	—	—	—	—	—				
Non-specific clinical populations	—	—	—	—	—	—	—				
Populations with liver-related conditions	3	1,498	36.0–47.5	40.6 (32.7–48.8)	4.9 (p = 0.09)	59.0% (0.0–88.3%)	0.0–100				
People who inject drugs	11	2,953	24.9–67.1	42.4 (33.6–51.4)	247.1 (p < 0.01)	96.0% (94.2–97.2%)	12.0–76.4				
Uzbekistan											
General population	6	2,411	4.5–29.0	9.6 (5.8–14.2)	50.8 (p < 0.01)	90.1% (82.1–94.5%)	0.3–28.1	6.5 (3.9–9.6)	32,364,996	3,107,040 (1,877,170–4,595,829)	2,100,359 (1,268,967–3,106,781)
Populations at intermediate risk	5	2,222	9.2–18.8	13.8 (11.1–16.9)	12.3 (p = 0.03)	59.3% (0.0–83.4%)	6.7–23.2				
Non-specific clinical populations	4	734	16.5–53.8	26.1 (15.8–37.9)	35.2 (p < 0.01)	82.8% (56.0–93.3%)	0.0–82.3				
Populations with liver-related conditions	4	382	16.6–41.9	29.8 (18.6–42.4)	17.4 (p < 0.01)	91.5% (81.3–96.1%)	0.0–84.9				
People who inject drugs	7	1,369	20.9–63.8	43.9 (31.8–56.4)	119.6 (p < 0.01)	95.0% (91.9–96.9%)	7.3–85.0				
All countries											
General population	49	984,397	0.0–29.0	2.2 (1.9–2.6)	3,707.0 (p = 0)	98.7% (98.6–98.8%)	0.5–4.6	1.5 (1.3–1.8)	66,008,999	3,595,313 (2,265,079–5,218,110)	2,430,431 (1,531,194–3,527,443)
Populations at intermediate risk	87	229,619	0.0–50.0	14.6 (12.8–16.5)	11,442.8 (p = 0)	99.2% (99.2–99.3%)	2.2–35.1				
Non-specific clinical populations	22	16,487	4.0–53.9	13.5 (10.9–16.4)	400.0 (p < 0.01)	94.8% (93.2–96.0%)	3.4–28.8				
Populations with liver-related conditions	10	3,988	16.7–47.5	31.6 (25.8–37.7)	114.8 (p < 0.01)	92.2% (87.7–95.0%)	12.7–54.3				
People who inject drugs	60	32,586	17.0–90.6	51.3 (46.9–55.6)	3561.5 (p = 0)	98.3% (98.2–98.5%)	19.1–82.8				

Table 4. Meta-analyses for hepatitis C virus (HCV) prevalence in Central Asia (CA) by risk population. Abbreviations: CI, confidence interval ^aQ: Cochran Q statistic assesses if heterogeneity is present in HCV prevalence estimates. ^bI²: Assesses the percentage of between-study variation that is due to true differences in HCV prevalence estimates across studies rather than chance. ^cPrediction interval: Estimates the 95% interval in which the true HCV prevalence in a new HCV study will lie. [†]This range is for all studies included in the meta-analyses database and covers the range of HCV prevalence across not only main HCV prevalence measures, but also across all strata.

		Univariable analysis				Multivariable analysis ^a	
		Number of studies	OR (95% CI)	p-value	Variance explained adjusted R ² (%)	AOR (95% CI)	p-value
Country	Kazakhstan	14	1	—		1	—
	Kyrgyzstan	22	2.0 (1.2–3.3)	0.006		2.0 (1.1–3.4)	0.015
	Tajikistan	6	3.0 (1.5–6.1)	0.003		2.8 (1.4–5.6)	0.006
	Uzbekistan	6	11.2 (5.6–22.7)	0.000	49.9	10.0 (4.6–21.7)	0.000
Low risk subpopulation	Blood donors	18	1	—		—	—
	General populations	22	1.6 (0.9–3.1)	0.134		—	—
	Pregnant women	8	1.0 (0.4–2.4)	0.942	1.5	—	—
Study site	Community	23	1	—		1	—
	Blood bank	8	0.6 (0.3–1.4)	0.229		0.9 (0.5–1.7)	0.745
	Antenatal clinics	17	0.5 (0.3–1.0)	0.061	4.2	0.8 (0.5–1.4)	0.438
Sample size	<100	3	1	—		1	—
	≥100	45	0.3 (0.1–0.9)	0.028	8.2	0.4 (0.1–1.0)	0.043
Sampling method	Probability-based	6	1			1	—
	Non-probability-based	40	0.5 (0.2–1.2)	0.126	3.1		
Year of data collection		48	0.9 (0.9–1.0)	0.026	8.4	1.0 (1.0–1.1)	0.654
Year of publication		48	1.0 (0.9–1.0)	0.149	2.4	—	—

Table 5. Univariable and multivariable meta-regression models for hepatitis C virus (HCV) prevalence among the general population in Central Asia (CA). Abbreviations: OR, odds ratio; AOR, adjusted odds ratio; CI, confidence interval. ^aThe adjusted R-squared for the full model was 51.4%.

countries^{53–55}. Furthermore, the challenging political climate in Uzbekistan has prevented the introduction of up-to-date healthcare guidelines and effective approaches to reduce HCV transmission in healthcare settings^{51,52}.

While no genotype information was available for Kyrgyzstan and Turkmenistan, pooled analysis on data from Kazakhstan, Tajikistan, and Uzbekistan suggest that HCV genotype 1 (53% of infections) and genotype 3 (38%) are the major circulating strains, but with strong presence of genotype 2 (9%; Table S5). While genotype 1 is common globally^{10,56}, its major presence may reflect healthcare-related exposures, given the frequency of identifying this genotype in clinical populations in CA^{42,43,57,58}, as well as the global association between this genotype and healthcare exposures⁵⁶. The major presence of genotype 3 may be due to injecting drug use being a major driver of incidence, given the global association between this genotype and injecting drug use⁵⁶, or may just reflect a sub-regional pattern—genotype 3 is the main circulating strain in each of Afghanistan^{13,59} and Pakistan⁵⁹, both of which are neighbouring countries of CA.

The pooled mean HCV prevalence in PWID indicated that over half of this population is already exposed to HCV (Table 4), similar to global trends^{60–62}. Notably, CA is geographically located along drug trafficking routes originating from Afghanistan^{7,63}, and is believed to have one of the highest rates of injecting drug use in the world⁶⁴. These factors further corroborate a major role for injecting drug use in transmission. Furthermore, with the high HCV prevalence found in prisoners (Table S2), incarceration could be influential in HCV transmission dynamics, just as in other regions^{62,65}. The high prevalence observed among sex workers (male, female, unspecified; Table S2) may suggest also high rates of injecting drug use in these populations, as supported by HIV biobehavioral surveillance data—sexual and injecting networks could be overlapping hotspots of both HCV and HIV transmission^{7,64}.

Despite progress in characterizing HCV epidemiology in CA, our study highlights key challenges and limitations to establishing a satisfactory understanding. Evidence varied by country, with no data identified from Turkmenistan (Fig. S8A). No data were available for high risk clinical populations, though healthcare could be a major mode of exposure, as it is in other soviet-era-related countries^{9,10,50}, and in countries with similar stage of development, e.g. in MENA^{11–19,66}. No data was identified for community-related exposures, e.g. informal healthcare, but such exposures could play a role as seen in other regions⁶⁷. There was an insufficient number of studies reporting HCV RNA prevalence in CA, a measure that informs assessment of chronic-infection prevalence, as antibody prevalence reflects both current infection as well as past infection (that is persons who spontaneously cleared the infection or were treated)⁶⁸.

Most available studies were descriptive—few had analytic epidemiologic designs where risk factors and modes of exposure could be ascertained. Most studies employed non-probability-based sampling, however, results of the meta-regressions indicated this had no effect on HCV prevalence in the general population, and therefore may not have limited the representativeness of reviewed data in our study. There was high heterogeneity in HCV prevalence measures (Table 4), but most heterogeneity (for the general population) was subsequently explained—differences by country were the main driver of prevalence variation (Table 5). A small-study effect was observed, with studies with a smaller sample size reporting higher HCV prevalence (Table 5), thereby potentially limiting the representativeness of reviewed data. HCV genotype data was relatively sparse, with no studies identified from Kyrgyzstan and Turkmenistan.

In spite of these limitations, a key strength of our study is that we identified a substantial number of studies, including a volume of unpublished data, in a significantly affected, but poorly understood region, thereby facilitating a synthesis of evidence and identification of knowledge gaps. A priority in addressing these gaps is to carry

out nationally-representative probability-based and population-based surveys in each of these countries. Such surveys can yield a precise estimate of HCV prevalence, delineation of spatial variability in infection exposure, identification of modes of transmission, and assessment of HCV knowledge and attitudes, as has been done in recent years in other countries, e.g. in Egypt^{15,69–74} and Pakistan^{11,75–77}.

Conclusion

In context of inadequate and underfunded healthcare systems^{8,52}, CA is one of the most affected regions by HCV infection. Uzbekistan, in particular, appears to be enduring one of the highest prevalence levels worldwide. HCV transmission appears to be driven by injecting drug use and healthcare exposures, with no evidence for declines in prevalence in recent years. Genotypes 1 and 3 are the most frequently-circulating strains, with some presence for genotype 2.

Our findings inform HCV response for public health planning, health service provision, development of HCV policy guidelines, and implementation of HCV programming to reduce transmission and associated disease burden. Achieving HCV elimination in CA by 2030 can only be accomplished by aggressive action and commitment, given the extent of challenges. There is an urgent need for expansion of affordable HCV testing and treatment for key populations, and targeted control based on settings of exposure. In context of this region being heavily affected by injecting drug use and the global opioid epidemic, harm reduction services must incorporate HCV services and be accessible to all PWID, by being expanded to all relevant settings, such as prisons. Nationally-representative probability-based population-based surveys must be conducted to precisely delineate HCV epidemiology in these countries and address the knowledge gaps, as identified in this study. Improving infection control in healthcare facilities is also warranted, such as through updating (otherwise outdated) clinical guidelines for healthcare workers⁵², and adopting safety-engineered syringes as recommended by WHO^{28,29}.

References

1. WHO. Global Hepatitis Report, 2017. Online at: <http://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/> (2017).
2. Brown, R. S. & Gaglio, P. J. Scope of worldwide hepatitis C problem. *Liver transplantation*. **9**(11), S10–S3 (2003).
3. Ayoub, H. & Abu-Raddad, L. J. Impact of treatment on hepatitis C virus transmission and incidence in Egypt: A case for treatment as prevention. *Journal of viral hepatitis*. **24**(6), 486–95 (2017).
4. World Health Organization. Global health sector strategy on viral hepatitis 2016–2021. Towards ending viral hepatitis. Online at: <http://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/> (2016).
5. World Health Organization. Combating hepatitis B and C to reach elimination by 2030: advocacy brief. Online at: <http://apps.who.int/iris/handle/10665/206453> (2016).
6. Batsaikhan, U. & Dabrowski, M. Central Asia—twenty-five years after the breakup of the USSR. *Russian Journal of Economics*. **3**(3), 296–320 (2017).
7. Thorne, C., Ferencic, N., Malyuta, R., Mimica, J. & Niemiec, T. Central Asia: hotspot in the worldwide HIV epidemic. *The Lancet Infectious Diseases*. **10**(7), 479–88 (2010).
8. McKee, M., Healy, J. & Falkingham, J. Health care in central Asia. Open University Press Buckingham (2002).
9. Mohd Hanafiah, K., Groeger, J., Flaxman, A. D. & Wiersma, S. T. Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence. *Hepatology*. **57**(4), 1333–42 (2013).
10. Gower, E., Estes, C., Blach, S., Razavi-Shearer, K. & Razavi, H. Global epidemiology and genotype distribution of the hepatitis C virus infection. *Journal of hepatology*. **61**(1), S45–S57 (2014).
11. Al-Kanaani, Z., Mahmud, S., Kouyoumjian, S. & Abu-Raddad, L. J. The epidemiology of hepatitis C virus in Pakistan: systematic review and meta-analyses Royal Society of Open. *Science*. **5**(4), 180257 (2008).
12. Mahmud, S., Akbarzadeh, V. & Abu-Raddad, L. J. The epidemiology of hepatitis C virus in Iran: systematic review and meta-analyses. *Scientific reports*. **8**(1), 150 (2018).
13. Chemaitelly, H., Mahmud, S., Rahmani, A. M. & Abu-Raddad, L. J. The epidemiology of hepatitis C virus in Afghanistan: systematic review and meta-analysis. *International Journal of Infectious Diseases*. **40**, 54–63 (2015).
14. Mohamoud, Y. A., Mumtaz, G. R., Riome, S., Miller, D. & Abu-Raddad, L. J. The epidemiology of hepatitis C virus in Egypt: a systematic review and data synthesis. *BMC infectious diseases*. **13**(1), 288 (2013).
15. Kouyoumjian, S., Chemaitelly, H. & Abu-Raddad, L. J. Characterizing hepatitis C virus epidemiology in Egypt: systematic reviews, meta-analyses, and meta-regressions. *Scientific Reports*. **8**(1), 1661 (2018).
16. Chemaitelly, H., Chaabna, K. & Abu-Raddad, L. J. The epidemiology of hepatitis C virus in the Fertile Crescent: systematic review and meta-analysis. *PloS one*. **10**(8), e0135281 (2015).
17. Fadlalla, F. A., Mohamoud, Y. A., Mumtaz, G. R. & Abu-Raddad, L. J. The epidemiology of hepatitis C virus in the maghreb region: systematic review and meta-analyses. *PloS one*. **10**(3), e0121873 (2015).
18. Mohamoud, Y. A., Riome, S. & Abu-Raddad, L. J. Epidemiology of hepatitis C virus in the Arabian Gulf countries: Systematic review and meta-analysis of prevalence. *International Journal of Infectious Diseases*. **46**, 116–25 (2016).
19. Chaabna, K., Kouyoumjian, S. P. & Abu-Raddad, L. J. Hepatitis C virus epidemiology in Djibouti, Somalia, Sudan, and Yemen: systematic review and meta-analysis. *PloS one*. **11**(2), e0149966 (2016).
20. Higgins, J. P. & Green, S. Cochrane handbook for systematic reviews of interventions: John Wiley & Sons (2011).
21. Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G. & Group, P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS medicine* **6**(7), e1000097 (2009).
22. Choo, Q.-L. *et al.* Isolation of a cDNA Clone Derived from a Blood-Borne Non-A, Non-B Viral Hepatitis Genome. *Science*. **244**(4902), 359 (1989).
23. Kuo, G. *et al.* IAn assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. *Science*. **244**(4902), 362–4 (1989).
24. Nelson, P. *et al.* The epidemiology of viral hepatitis among people who inject drugs: results of global systematic reviews. *Lancet*. **378**(9791), 571 (2011).
25. Lavanchy D. Evolving epidemiology of hepatitis C virus. *Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases*. **17**(2):107–15. Epub 2010/11/26, <https://doi.org/10.1111/j.1469-0691.2010.03432.x>. PubMed PMID: 21091831.(2011)
26. Freeman, M. F. & Tukey, J. W. Transformations related to the angular and the square root. *The Annals of Mathematical Statistics*. 607–11. (1950)
27. Borenstein, M., Hedges, L. V., Higgins, J. P. T. & Rothstein, H. R. *Front Matter*, in *Introduction to Meta-Analysis*. Chichester, UK: John Wiley & Sons, Ltd (2009).

28. Higgins, J. P., Thompson, S. G., Deeks, J. J. & Altman, D. G. Measuring inconsistency in meta-analyses. *BMJ: British Medical Journal*. **327**(7414), 557 (2003).
29. Higgins, J., Thompson, S. G. & Spiegelhalter, D. J. A re-evaluation of random-effects meta-analysis. *Journal of the Royal Statistical Society: Series A (Statistics in Society)*. **172**(1), 137–59 (2009).
30. Harfouche, M. *et al.* Hepatitis C virus viremic rate in the Middle East and North Africa: Systematic synthesis, meta-analyses, and meta-regressions. *PLoS one*. **12**(10), e0187177 (2017).
31. Ayoub, H. H., Chemaitelly, H., Omori, R. & Abu-Raddad, L. J. Hepatitis C virus infection spontaneous clearance: Has it been underestimated? *International Journal of Infectious Diseases*. **75**, 60–6 (2018).
32. United Nations, Department of Economic and Social Affairs, Population Division. World Population Prospects: The 2017 Revision. Available at: <https://population.un.org/wpp/DataQuery/> (2017).
33. Schwarzer G., Abu-Raddad L. J., Chemaitelly H. & Rucker G. Seriously misleading result using inverse of Freeman-Tukey double arcsine transformation in meta-analysis of single proportions (under review).
34. Shannon, C. E. A mathematical theory of communication. *ACM SIGMOBILE Mobile Computing and Communications Review*. **5**(1), 3–55 (2001).
35. Schwarzer, G. General Package for Meta-Analysis. Version 4.1–0. Available at: <http://cran.r-project.org/web/packages/meta/meta.pdf>.
36. Team RC. R: A language and environment for statistical computing (2013).
37. StataCorp. Stata Statistical Software: Release 13. College Station, TX: StataCorp LP. (2013).
38. Begaidarova, R. *et al.* Assessment of the severity of immunodeficiency in patients of Asian ethnicity with HIV/HCV co-infection. *Georgian medical news*. **254**, 53–6 (2016).
39. Mirojov, G. *et al.* Prevalence, etiological factors, survival rates, lifetime and causes of death of patients with liver cirrhosis in Tajikistan. *Hepatology International*. **7**:S529, <https://doi.org/10.1007/s12072-013-9429-0>. PubMed PMID: 71308897 (2013).
40. Алсалих Н, Сычев Д, Подопригра И. Распространенность вирусного гепатита С среди трудовых мигрантов, прибывающих в Российскую Федерацию. Электронный научно-образовательный вестник «Здоровье и образование в XXI веке». 2017;19(7).
41. Azimova, S. M., Dustov, A. & Tursunov, R. Chronic hepatitis “C” in Tajikistan [Russian]. *Avicenna Tajik State Medical University*. **2**(63), 82–9 (2015).
42. Khan, A. *et al.* Epidemiological and clinical evaluation of hepatitis B, hepatitis C, and delta hepatitis viruses in Tajikistan. *J Med Virol*. **80**(2):268–76. Epub 2007/12/22, <https://doi.org/10.1002/jmv.21057>. PubMed PMID: 18098133 (2008).
43. Kurbanov, F. *et al.* Hepatitis C virus molecular epidemiology in Uzbekistan. *J Med Virol*. **69**(3):367–75. Epub 2003/01/15, <https://doi.org/10.1002/jmv.10298>. PubMed PMID: 12526047 (2003).
44. Beyrer, C. *et al.* Characterization of the emerging HIV type 1 and HCV epidemics among injecting drug users in Dushanbe, Tajikistan. *AIDS Res Hum Retroviruses*. **25**(9):853–60. Epub 2009/08/20, <https://doi.org/10.1089/aid.2008.0206>. PubMed PMID: 19689193; PubMed Central PMCID: PMC2858926 (2009).
45. Nurgalieva, Z. Z., Hollinger, F. B., Graham, D. Y., Zhangabylova, S. & Zhangbylov, A. Epidemiology and transmission of hepatitis B and C viruses in Kazakhstan. *World Journal of Gastroenterology*. **13**(8):1204–7. PubMed PMID: 2007184913 (2007).
46. United Nations DESA/Population Division. Revision of World Urbanization Prospects. Online at: <https://population.un.org/wup/> (2018).
47. UNAIDS Country factsheets: Uzbekistan Online at: <http://www.unaids.org/en/regionscountries/countries/uzbekistan> (2017).
48. Kamal, S. M. Acute hepatitis C: a systematic review. *The American journal of gastroenterology*. **103**(5), 1283 (2008).
49. Polaris Observatory. Online at: <http://cdfafound.org/polaris-hepC-dashboard/>.
50. Batash, S., Khaykis, I., Raicht, R. F. & Bini, E. J. High prevalence of hepatitis C virus infection among immigrants from the former Soviet Union in the New York City metropolitan area: results of a community-based screening program. *Am J Gastroenterol*.; **103**(4):922–7. Epub 2008/04/10, <https://doi.org/10.1111/j.1572-0241.2008.01789.x>. PubMed PMID: 18397420 (2008).
51. Ruzibakiev, R. *et al.* Risk factors and seroprevalence of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus infection in Uzbekistan. *Intervirology*. **44**(6), 327–32 (2001).
52. Marquez, P. V. Blood services in Central Asian health systems: a clear and present danger of spreading HIV/AIDS and other infectious diseases. 2008.
53. Simonsen, L., Kane, A., Lloyd, J., Zaffran, M. & Kane, M. Unsafe injections in the developing world and transmission of bloodborne pathogens: a review. *Bulletin of the World Health Organization*. **77**(10):789–800. Epub 1999/12/11. PubMed PMID: 10593026; PubMed Central PMCID: PMC2557743 (1999).
54. Hutin, Y. J., Hauri, A. M. & Armstrong, G. L. Use of injections in healthcare settings worldwide, 2000: literature review and regional estimates. *Bmj*. **327**(7423), 1075 (2003).
55. Kane, A., Lloyd, J., Zaffran, M., Simonsen, L. & Kane, M. Transmission of hepatitis B, hepatitis C and human immunodeficiency viruses through unsafe injections in the developing world: model-based regional estimates. *Bulletin of the World Health Organization*. **77**(10), 801 (1999).
56. Messina, J. P. *et al.* Global distribution and prevalence of hepatitis C virus genotypes. *Hepatology*. **61**(1), 77–87 (2015).
57. Viazov, S. *et al.* Hepatitis C virus genotypes in different regions of the former Soviet Union (Russia, Belarus, Moldova, and Uzbekistan). *J Med Virol*.; **53**(1):36–40. Epub 1997/09/23. PubMed PMID: 9298730 (1997).
58. Kurbanov, F. *et al.* Molecular epidemiology and interferon susceptibility of the natural recombinant hepatitis C virus strain RF1_2k/1b. *Journal of Infectious Diseases*. **198**(10):1448–56, <https://doi.org/10.1086/592757>. PubMed PMID: 2008506636. (2008).
59. Mahmud, S. *et al.* Hepatitis C virus genotypes in the Middle East and North Africa: Distribution, diversity, and patterns. *Journal of medical virology*. **90**(1), 131–41 (2018).
60. Mumtaz, G. R. *et al.* HIV among people who inject drugs in the Middle East and North Africa: systematic review and data synthesis. *PLoS medicine*. **11**(6), e1001663 (2014).
61. Mumtaz, G. R., Weiss, H. A., Vickerman, P., Larke, N. & Abu-Raddad, L. J. Using hepatitis C prevalence to estimate HIV epidemic potential among people who inject drugs in the Middle East and North Africa. *AIDS (London, England)*. **29**(13), 1701 (2015).
62. Larney, S. *et al.* Incidence and prevalence of hepatitis C in prisons and other closed settings: results of a systematic review and meta-analysis. *Hepatology*. **58**(4), 1215–24 (2013).
63. Drugs UNOo, Asia CROfC. Illicit Drug Trends in Central Asia. 2008.
64. El-Bassel, N., Strathdee, S. A. & El Sadr, W. M. HIV and people who use drugs in central Asia: confronting the perfect storm. *Drug & Alcohol Dependence*. **132**, S2–S6 (2013).
65. Heijnen, M., Mumtaz, G. R. & Abu-Raddad, L. J. Status of HIV and hepatitis C virus infections among prisoners in the Middle East and North Africa: review and synthesis. *Journal of the International AIDS Society*. **19**(1) (2016).
66. Harfouche, M. *et al.* Epidemiology of hepatitis C virus among hemodialysis patients in the Middle East and North Africa: systematic syntheses, meta-analyses, and meta-regressions. *Epidemiology & Infection*. **145**(15), 3243–63 (2017).
67. Mahmud, S., Kouyoumjian, S. P., Al Kanaani, Z., Chemaitelly, H. & Abu-Raddad, L. J. Individual-level key associations and modes of exposure for hepatitis C virus infection in the Middle East and North Africa: a systematic synthesis. *Annals of epidemiology* (2018).

68. Chen, S. L. & Morgan, T. R. The natural history of hepatitis C virus (HCV) infection. *International journal of medical sciences*. ;3(2):47–52. Epub 2006/04/15. PubMed PMID: 16614742; PubMed Central PMCID: PMC1415841. (2006)
69. El-Zanaty F, W. A. Egypt Demographic and Health Survey 2008. *Cairo: Egyptian Ministry of Health, National Population Council, El-Zanaty and Associates, and ORC Macro*. <https://dhsprogram.com/publications/publication-fr220-dhs-final-reports.cfm> (2008).
70. Cuadros, D. F., Branscum, A. J., Miller, F. D. & Abu-Raddad, L. J. Spatial epidemiology of hepatitis C virus infection in Egypt: analyses and implications. *Hepatology*. **60**(4), 1150–9 (2014).
71. Miller, F. D. & Abu-Raddad, L. J. Evidence of intense ongoing endemic transmission of hepatitis C virus in Egypt. *Proceedings of the National Academy of Sciences*. **107**(33):14757–62 (2010).
72. Chemaitelly, H., Abu-Raddad, L. J. & Miller, F. D. An apparent lack of epidemiologic association between hepatitis C virus knowledge and the prevalence of hepatitis C infection in a national survey in Egypt. *PLoS one*. **8**(7), e69803 (2013).
73. Benova, L., Awad, S. F., Miller, F. D. & Abu-Raddad, L. J. Estimation of hepatitis C virus infections resulting from vertical transmission in Egypt. *Hepatology*. **61**(3), 834–42 (2015).
74. Guerra, J., Garenne, M., Mohamed, M. & Fontanet, A. HCV burden of infection in Egypt: results from a nationwide survey. *Journal of viral hepatitis*. **19**(8), 560–7 (2012).
75. Umar, M. *et al.* Hepatitis C in Pakistan: a review of available data. *Hepatitis monthly*. **10**(3), 205 (2010).
76. Qureshi, H., Bile, K., Joona, R., Alam, S. & Afridi, H. Prevalence of hepatitis B and C viral infections in Pakistan: findings of a national survey appealing for effective prevention and control measures. *Eastern Mediterranean Health Journal*. **16**, S15 (2010).
77. Benova, L., Awad, S. F. & Abu-Raddad, L. J. Estimate of vertical transmission of Hepatitis C virus in Pakistan in 2007 and 2012 birth cohorts. *Journal of viral hepatitis* (2017).
78. Skorikova, S. V., Burkitbaev, Z. K., Savchuk, T. N. & Zhiburt, E. B. [Prevalence and incidence of infections among blood donors in Astana]. *Vopr Virusol*. **60**(1):34–6. Epub 2015/05/30. PubMed PMID: 26021072 (2015).
79. El-Bassel, N. *et al.* Implications of mobility patterns and HIV risks for HIV prevention among migrant market vendors in Kazakhstan. *Am J Public Health*. **101**(6):1075–81. Epub 2011/04/16. doi: 10.2105/ajph.2010.300085. PubMed PMID: 21493929; PubMed Central PMCID: PMC3093276 (2011).
80. Джумагалиева А, Орақбай Л, Омарова М, Шуратов И. Анализ эпидемиологических параметров гепатита а в ряде регионов Казахстана. *Современные проблемы науки и образования*. (1–1). (2015).
81. Khasenova, G. The results of sentinel epidemiological surveillance among pregnant women in Kazakhstan, 2006. In Russian: Результаты дозорного эпидемиологического надзора среди беременных женщин, Казахстан, 2006 год. *Almaty 2007*.
82. Data from Kazakhstan Blood Center. 2015.
83. Tashtemirov, K., Imangazinov, S., Tashtemirova, O. & Egoshin, V. Donation and some problems of defect donor's blood. *Georgian medical news*. **261**, 80–8 (2016).
84. Mamaev, T. M. The results of sentinel surveillance of HIV infection among pregnant women, Kyrgyzstan, 2005. In Russian: Результаты дозорного эпидемиологического надзора за ВИЧ инфекцией среди беременных женщин, Кыргызстан, 2005. Republican AIDS Association, Osh Oblast AIDS Centre. Bishkek, 2006. Provided by the WHO Country Office Kyrgyzstan.
85. Djumagulova, A. Ş. IKA. The situation on viral hepatitis in the Kyrgyz Republic [Russian] (2016).
86. Baimakhanov, Z. *et al.* editors. *Liver transplantation in Kazakhstan: current status*. *Transplant International*; 2017: Wiley 111 Rivert St, Hoboken 07030–5774, NJ USA.
87. Bahovadinov, B., Tretyakova, A., Aripova, D. & Edalieva, C. Prevalence of markers of hemotransmitted infections among donors of Tajikistan. *Vox Sanguinis*;99:272, <https://doi.org/10.1111/j.1423-0410.2010.01343-2.x>. PubMed PMID: 70237438 (2010).
88. Abdurashit, R., Shakhnoza, N. & Yakov, A. Results of sentinel surveillance of HIV infection amongst pregnant women in Tajikistan 2005–2007. *Tajikistan*, www.ncc.tj/images/DEN/pregnant%20_eng.pdf (2008).
89. Ruzibakiev R. *et al.* Risk factors and seroprevalence of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus infection in Uzbekistan. *Intervirology*. **44**(6):327–32. Epub 2002/01/24. PubMed PMID: 11805437 (2001).
90. Berger, S. *Infectious Diseases of Uzbekistan*: GIDEON Informatics Inc (2015).
91. Ni, Y. Q. *et al.* Clinical epidemiological analysis of 3602 cases of primary liver cancer in Xinjiang. [Chinese]. *Chinese Journal of Oncology*. **34**(5):374–7, <https://doi.org/10.3760/cma.j.issn.0253-3766.2012.05.012> PubMed PMID: 2012347911 (2012).
92. Nersesov, A. V. *et al.* Epidemiological and clinical characteristics of hepatocellular carcinoma in Kazakhstan. *Hepatology International*. ;11 (1 Supplement 1):S388. PubMed PMID: 614580527 (2017).
93. Deryabina, A., Patnaik, P., Gwynn, C. & El-Sadr, W. M. Sexual transmission of HIV and possible underreporting of drug use in Kazakhstan. *Topics in Antiviral Medicine*. **23**:474. PubMed PMID: 72119923 (2015).
94. Zhussupov, B. *et al.* Study of behaviors associated with HIV infection, STI and viral hepatitis among injecting drug users in Temirtau and Karaganda, Republic of Kazakhstan. *Central Asia Office* (2007).
95. Gilbert, L. *et al.* Couple-Based HIV Prevention for Injecting Drug Users in Kazakhstan: A Pilot Intervention Study. *Journal of Prevention & Intervention in the Community*. **38**(2), 162–76, <https://doi.org/10.1080/10852351003640914> (2010).
96. El-Bassel, N. *et al.* Effects of a couple-based intervention to reduce risks for HIV, HCV, and STIs among drug-involved heterosexual couples in Kazakhstan: a randomized controlled trial. *J Acquir Immune Defic Syndr*. **2014**;67(2):196–203. Epub 2014/07/06. PubMed PMID: 24991973; PubMed Central PMCID: PMC34162759, <https://doi.org/10.1097/qai.0000000000000277>.
97. El-Bassel, N. *et al.* HIV risks among injecting and non-injecting female partners of men who inject drugs in Almaty, Kazakhstan: implications for HIV prevention, research, and policy. *Int J Drug Policy*. ;25(6):1195–203. Epub 2014/02/22. PubMed PMID: 24556208, <https://doi.org/10.1016/j.drugpo.2013.11.009> (2014).
98. El-Bassel, N. *et al.* HIV among injection drug users and their intimate partners in Almaty, Kazakhstan. *AIDS Behav*. **17**(7):2490–500. Epub 2013/04/25, <https://doi.org/10.1007/s10461-013-0484-2>. PubMed PMID: 23612942 (2013).
99. Т Забрansky, V. Mravcik (Eds.), *The Regional Report on Drug Situation in Central Asia [Региональный обзор о наркоситуации в Центральной Азии]* (1st ed.), Prague ResAd (2013).
100. Soliev, A. Analysis on epidemiological situation and responses based on second generation sentinel surveillance system among injecting drug users, Tajikistan, Kazakhstan, Kyrgyzstan, 2006–2009. Presented at the regional conference: HIV infection epidemic in Central Asia: further development of epidemiological surveillance; Almaty, May 18–19 (2010).
101. Ganina, L. Y., Elizariyeva, L. & Kaspirova, A. Report: Overview of the epidemiological situation of HIV in the Republic of Kazakhstan in 2013–2015. Republican Center on Prevention and Control of AIDS.
102. Rosenkranz, M. *et al.* Assessment of health services for people who use drugs in Central Asia: findings of a quantitative survey in Kazakhstan and Kyrgyzstan. *Harm reduction journal*. **13**(1), 3 (2016).
103. Drew, R. & Choudhri, Y. Assessment of HIV/AIDS surveillance in the Europe and Eurasia Region. USAID (2005).
104. Kurbanov, F. *et al.* Human immunodeficiency virus in Uzbekistan: epidemiological and genetic analyses. *AIDS Res Hum Retroviruses*. **19**(9):731–8. Epub 2003/10/31, <https://doi.org/10.1089/088922203769232520>. PubMed PMID: 14585203 (2003).
105. Inogamov, Z. I. The results of sentinel surveillance of HIV infection among injecting drug users in 14 sentinel sites of the Republic of Uzbekistan, 2007. Presented at: State of the HIV epidemic in the Republic of Uzbekistan Results of the SS in, Tashkent, Uzbekistan, 18–21 August 2008 (2007).

Acknowledgements

This publication was made possible by NPRP grant 9-040-3-008 from the Qatar National Research Fund (a member of Qatar Foundation). The statements made herein are solely the responsibility of the authors. The authors are also grateful for infrastructure support provided by the Biostatistics, Epidemiology, and Biomathematics Research Core at Weill Cornell Medicine-Qatar.

Author Contributions

Welathanthrige S.P. Botheju, Fawzi Zghyer and Sarwat Mahmud conducted the systematic review of the literature, data retrieval, extraction, and analysis, and wrote the first draft of the paper. Assel Terlikbayeva and Nabila El-Bassel contributed data and participated in the drafting of this article. Laith J. Abu-Raddad conceived and led the design of the study, analyses, and drafting of the article. All authors read, amended, and approved the final manuscript.

Additional Information

Supplementary information accompanies this paper at <https://doi.org/10.1038/s41598-019-38853-8>.

Competing Interests: The authors declare no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2019